[144] Catalyst Pharmaceutical Inc. SEC Filing
Catalyst Pharmaceuticals (CPRX) reports a proposed Rule 144 sale of 20,000 common shares, to be transacted through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $401,514.10. The shares were acquired on 09/03/2025 via exercise of options originally granted on 12/19/2018, and payment for those shares is noted as cash. The filing indicates 122,391,010 shares outstanding for the issuer and states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Catalyst Pharmaceuticals (CPRX) segnala una proposta di vendita ai sensi della Rule 144 di 20.000 azioni ordinarie, che saranno negoziate tramite Fidelity Brokerage Services su NASDAQ per un valore complessivo di $401,514.10. Le azioni sono state acquisite il 09/03/2025 mediante l’esercizio di opzioni originariamente concesse il 12/19/2018, e il pagamento è stato effettuato in contanti. La comunicazione riporta 122,391,010 azioni in circolazione dell’emittente e specifica che il soggetto dichiarante non ha venduto titoli negli ultimi tre mesi. L’avviso include la consueta dichiarazione che il venditore non è a conoscenza di informazioni materiali negative non divulgate riguardanti l’emittente.
Catalyst Pharmaceuticals (CPRX) informa sobre una propuesta de venta bajo la Regla 144 de 20.000 acciones ordinarias, que se negociarán a través de Fidelity Brokerage Services en NASDAQ por un valor agregado de $401,514.10. Las acciones se adquirieron el 09/03/2025 mediante el ejercicio de opciones originalmente otorgadas el 12/19/2018, y el pago se realizó en efectivo. La presentación indica que hay 122,391,010 acciones en circulación del emisor y declara que la persona que informa no vendió valores en los últimos tres meses. El aviso incluye la habitual manifestación de que el vendedor no conoce información material adversa no divulgada sobre el emisor.
Catalyst Pharmaceuticals (CPRX)는 20,000 보통주에 대한 Rule 144 규정에 따른 매도 제안을 보고했으며, 해당 주식은 Fidelity Brokerage Services를 통해 NASDAQ에서 총액 $401,514.10로 거래될 예정입니다. 해당 주식은 12/19/2018에 원래 부여된 옵션을 09/03/2025에 행사하여 취득했으며, 지급 방식은 현금으로 기재되어 있습니다. 제출서류에는 발행사의 유통 주식 수가 122,391,010주로 기재되어 있고, 보고인은 최근 3개월 동안 증권을 매도한 바 없다고 명시되어 있습니다. 해당 통지에는 매도인이 발행사에 대해 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 일반적인 진술이 포함되어 있습니다.
Catalyst Pharmaceuticals (CPRX) signale une proposition de vente en vertu de la Rule 144 portant sur 20,000 actions ordinaires, qui seront négociées via Fidelity Brokerage Services sur le NASDAQ pour une valeur totale de $401,514.10. Les actions ont été acquises le 09/03/2025 par exercice d’options initialement accordées le 12/19/2018, et le paiement a été effectué en espèces. le dossier indique 122,391,010 actions en circulation de l’émetteur et précise que la personne déclarante n’a pas vendu de titres au cours des trois derniers mois. L’avis comprend la déclaration habituelle selon laquelle le vendeur n’a pas connaissance d’informations défavorables importantes non divulguées concernant l’émetteur.
Catalyst Pharmaceuticals (CPRX) meldet einen vorgeschlagenen Verkauf nach Rule 144 von 20.000 Stammaktien, die über Fidelity Brokerage Services an der NASDAQ mit einem Gesamtwert von $401,514.10 gehandelt werden sollen. Die Aktien wurden am 09/03/2025 durch Ausübung von ursprünglich am 12/19/2018 gewährten Optionen erworben, die Zahlung erfolgte in Bargeld. Die Einreichung gibt 122,391,010 ausstehende Aktien des Emittenten an und erklärt, dass die meldende Person in den letzten drei Monaten keine Wertpapiere verkauft hat. Die Mitteilung enthält die übliche Zusicherung, dass der Verkäufer über keine nicht offengelegten wesentlichen nachteiligen Informationen zum Emittenten informiert ist.
- Full Rule 144 disclosure provided, including broker, share count, and aggregate market value
- Securities originated from option exercise (options granted 12/19/2018) with payment in cash
- No sales in past three months reported for the selling person, reducing aggregation complexity
- Transaction size is small relative to total outstanding shares (20,000 vs. 122,391,010)
- None.
Insights
TL;DR: Routine Rule 144 notice disclosing an intended sale of 20,000 shares acquired by option exercise; immaterial to outstanding share count.
This filing documents a planned sale under Rule 144 of 20,000 common shares valued at approximately $401,514.10. The shares were acquired by exercise of options granted in 2018 and paid for in cash on the acquisition date. Against the issuer's reported outstanding share base of 122,391,010, this planned sale represents a de minimis percentage, suggesting limited direct market impact. The filer also reports no sales in the prior three months and makes the standard attestation regarding undisclosed material information.
TL;DR: Compliance-focused disclosure that meets Rule 144 reporting requirements; no governance red flags disclosed.
The form provides required disclosure about the origin of the securities (options granted 12/19/2018) and the mechanics of the proposed sale through a named broker. There is no indication in the document of unusual settlement terms, aggregation with other sellers, or recent insider sales. The representation about lack of undisclosed material information is standard. Based solely on the notice, there are no governance concerns evident from this transaction.
Catalyst Pharmaceuticals (CPRX) segnala una proposta di vendita ai sensi della Rule 144 di 20.000 azioni ordinarie, che saranno negoziate tramite Fidelity Brokerage Services su NASDAQ per un valore complessivo di $401,514.10. Le azioni sono state acquisite il 09/03/2025 mediante l’esercizio di opzioni originariamente concesse il 12/19/2018, e il pagamento è stato effettuato in contanti. La comunicazione riporta 122,391,010 azioni in circolazione dell’emittente e specifica che il soggetto dichiarante non ha venduto titoli negli ultimi tre mesi. L’avviso include la consueta dichiarazione che il venditore non è a conoscenza di informazioni materiali negative non divulgate riguardanti l’emittente.
Catalyst Pharmaceuticals (CPRX) informa sobre una propuesta de venta bajo la Regla 144 de 20.000 acciones ordinarias, que se negociarán a través de Fidelity Brokerage Services en NASDAQ por un valor agregado de $401,514.10. Las acciones se adquirieron el 09/03/2025 mediante el ejercicio de opciones originalmente otorgadas el 12/19/2018, y el pago se realizó en efectivo. La presentación indica que hay 122,391,010 acciones en circulación del emisor y declara que la persona que informa no vendió valores en los últimos tres meses. El aviso incluye la habitual manifestación de que el vendedor no conoce información material adversa no divulgada sobre el emisor.
Catalyst Pharmaceuticals (CPRX)는 20,000 보통주에 대한 Rule 144 규정에 따른 매도 제안을 보고했으며, 해당 주식은 Fidelity Brokerage Services를 통해 NASDAQ에서 총액 $401,514.10로 거래될 예정입니다. 해당 주식은 12/19/2018에 원래 부여된 옵션을 09/03/2025에 행사하여 취득했으며, 지급 방식은 현금으로 기재되어 있습니다. 제출서류에는 발행사의 유통 주식 수가 122,391,010주로 기재되어 있고, 보고인은 최근 3개월 동안 증권을 매도한 바 없다고 명시되어 있습니다. 해당 통지에는 매도인이 발행사에 대해 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 일반적인 진술이 포함되어 있습니다.
Catalyst Pharmaceuticals (CPRX) signale une proposition de vente en vertu de la Rule 144 portant sur 20,000 actions ordinaires, qui seront négociées via Fidelity Brokerage Services sur le NASDAQ pour une valeur totale de $401,514.10. Les actions ont été acquises le 09/03/2025 par exercice d’options initialement accordées le 12/19/2018, et le paiement a été effectué en espèces. le dossier indique 122,391,010 actions en circulation de l’émetteur et précise que la personne déclarante n’a pas vendu de titres au cours des trois derniers mois. L’avis comprend la déclaration habituelle selon laquelle le vendeur n’a pas connaissance d’informations défavorables importantes non divulguées concernant l’émetteur.
Catalyst Pharmaceuticals (CPRX) meldet einen vorgeschlagenen Verkauf nach Rule 144 von 20.000 Stammaktien, die über Fidelity Brokerage Services an der NASDAQ mit einem Gesamtwert von $401,514.10 gehandelt werden sollen. Die Aktien wurden am 09/03/2025 durch Ausübung von ursprünglich am 12/19/2018 gewährten Optionen erworben, die Zahlung erfolgte in Bargeld. Die Einreichung gibt 122,391,010 ausstehende Aktien des Emittenten an und erklärt, dass die meldende Person in den letzten drei Monaten keine Wertpapiere verkauft hat. Die Mitteilung enthält die übliche Zusicherung, dass der Verkäufer über keine nicht offengelegten wesentlichen nachteiligen Informationen zum Emittenten informiert ist.
FAQ
What does the Form 144 filed by CPRX disclose?
How were the 20,000 CPRX shares acquired?
What is the issuer's reported number of shares outstanding?
Does the filing report any sales by the same person in the past three months?
Through which broker will the CPRX shares be sold?
